Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Percutaneous Heart Valves May Demand Novel Regulatory Approach

This article was originally published in The Gray Sheet

Executive Summary

Leading innovators hope to blaze a trail through what some see as formidable regulatory barriers to technological advances allowing diseased aortic valves to be replaced percutaneously

You may also be interested in...



Sleep Physicians Criticize CMS Proposal To Allow Home Tests For CPAP

Sleep disorder physicians' groups want CMS to require qualified professional oversight as a condition of coverage for home testing of obstructive sleep apnea

Sleep Physicians Criticize CMS Proposal To Allow Home Tests For CPAP

Sleep disorder physicians' groups want CMS to require qualified professional oversight as a condition of coverage for home testing of obstructive sleep apnea

People In Brief

Stentys adds regulatory exec: Paris-based start-up signals its intention to take the next steps in development of its coronary bifurcation lesion drug-eluting stent with the Feb. 21 appointment of Luc Morisset as director of regulatory affairs. Stentys plans to start feasibility studies by mid-year. Its technology allows a stent to open to a side branch vessel without relying on accurate positioning by the clinician, according to the firm. Morisset spent the last decade as director of regulatory affairs for MedPass International, a European medtech consulting firm. He also worked more than five years at the French Ministry of Health where he was involved in medical device approvals. Morisset joins CEO Gonzague Issenmann, who co-founded the firm in 2005 after leaving his position as finance controller for Johnson & Johnson/Cordis' European unit. Stentys co-founder and "non-executive" president Jacques Séguin is also currently CEO of Irvine, Calif.-based CoreValve, which is developing the ReValving system for percutaneous aortic valve replacement (1"The Gray Sheet" Oct. 30, 2006, p. 9)...

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel